1
|
Albalawi E. Genetic Rearrangements in Different Salivary Gland Tumors: A Systematic Review. Cureus 2024; 16:e61639. [PMID: 38966479 PMCID: PMC11223175 DOI: 10.7759/cureus.61639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/04/2024] [Indexed: 07/06/2024] Open
Abstract
Salivary gland tumors (SGT) encompass a wide range of neoplasms, each with its own unique histological type and clinical presentation. This review hones in on prevalent subtypes of SGTs, including adenoid cystic carcinoma (ACC), salivary duct carcinoma (SDC), and polymorphous adenocarcinoma (PAC). The articles, identified through specific keywords, were meticulously screened in databases like PubMed, Scopus, Google Scholar, and Web of Science from 2018 to 2023. Eight articles delved into genetic modifications among the selected SGT types. A fusion protein known as MYB-NF1B is typically associated with ACC, promoting cell proliferation while inhibiting apoptosis. The presence of MYB modifications in ACCs is a beacon of hope, as it is linked to a more favorable prognosis. In contrast, SDCs often exhibit HER2 expression. The invasive nature of SGTs contributes to their resistance to treatment. In the case of PAC, the role of PRKD1 is particularly noteworthy. PRKD1, integrated with other genes from the PRKD1/2/3 cluster, helps to differentiate PAC from other diseases. Furthermore, the genetic profiles of KTN1-PRKD1) and PPP2R2A:PRKD1 are distinct. The significant genetic variability among SGTs necessitates meticulous examination. This field is in a constant state of evolution, with new discoveries reshaping our understanding. Genetics is a key player in deciphering SGTs and tailoring treatments. This complex neoplasm demands ongoing research to uncover all genetic influences, thereby enhancing diagnostic methodologies, therapeutic strategies, and patient outcomes.
Collapse
|
2
|
Papanikolaou V, Chrysovergis A, Adamopoulou M, Spyropoulou D, Roukas D, Papanastasiou G, Mastronikoli S, Papouliakos S, Manaios L, Tsiambas E, Pantos P, Ragos V, Fotiades P, Peschos D, Mastronikolis N, Kyrodimos E. PTEN Deregulation Mechanisms in Salivary Gland Carcinomas. CANCER DIAGNOSIS & PROGNOSIS 2024; 4:25-29. [PMID: 38173659 PMCID: PMC10758848 DOI: 10.21873/cdp.10280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 11/13/2023] [Indexed: 01/05/2024]
Abstract
Among the tumour suppressor genes that affect critically cell functions and homeostasis, phosphatase and tensin homolog deleted in chromosome 10 (PTEN- gene locus: 10q21) regulates the PI3K/Akt/mTOR signalling pathway. PTEN is deleted, mutated or epigenetically hyper-methylated in a variety of human solid malignancies. Salivary gland carcinomas (SGCs) belong to the head and neck carcinomas (HNCs) super category of solid malignancies. Histo-pathologically, they demonstrate a significant diversity due to a variety of distinct and mixed subtypes. Genetically, they are characterized by a broad spectrum of gene and chromosomal imbalances. Referring specifically to suppressor genes, PTEN deregulation plays a critical role in signaling transduction in the corresponding SGC pre- and malignant epithelia modifying the response rates to potential targeted therapeutic strategies. In the current review, we explored the role of PTEN deregulation mechanisms that are involved in the onset and progression of SGCs.
Collapse
Affiliation(s)
- Vasileios Papanikolaou
- First Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece
| | - Aristeidis Chrysovergis
- First Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece
| | - Maria Adamopoulou
- Biomedical Sciences Program, Department of Science and Mathematics, Deree American College, Athens, Greece
| | - Despoina Spyropoulou
- Department of Radiation Oncology, Medical School, University of Patras, Patras, Greece
| | - Dimitrios Roukas
- Department of Psychiatry, 417 Veterans Army Hospital (NIMTS), Athens, Greece
| | - George Papanastasiou
- Department of Maxillofacial Surgery, Medical School, University of Ioannina, Ioannina, Greece
| | | | | | | | - Evangelos Tsiambas
- Department of Cytology, 417 Veterans Army Hospital (NIMTS), Athens, Greece
| | - Pavlos Pantos
- First Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece
| | - Vasileios Ragos
- Department of Maxillofacial Surgery, Medical School, University of Ioannina, Ioannina, Greece
| | | | - Dimitrios Peschos
- Department of Physiology, Medical School, University of Ioannina, Ioannina, Greece
| | | | - Efthymios Kyrodimos
- First Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece
| |
Collapse
|